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Abstract
Background: To explore the feasibility, the efficacy, and the mechanism of mandibular advancement devices
(MAD) in the treatment of persistent sleep apnea after surgery.
Methods: Nineteen patients who failed uvulopalatopharyngoplasty (UPPP) or UPPP plus genioglossus advancement and
hyoid myotomy (GAHM) were given a non-adjustable MAD for treatment. All patients had polysomnography (PSG) at
least 6 months post-UPPP with and without the MAD. Seventeen patients had computed tomography (CT) examinations.
Results: After the application of MAD, the apnea hypopnea index (AHI) decreased significantly from 41.2 ± 13.1/h to 10.
1 ± 5.6/h in the responder group. The response rate was 57.9% (11/19). During sleep apnea/hypopnea acquired from
sedated sleep, the cross-sectional area and anterior-posterior and lateral diameters of the velopharynx enlarged
significantly from 4.2 ± 6.0 mm2 to 17.5 ± 15.3 mm2, 1.9 ± 2.3 mm to 6.5 ± 4.1 mm, and 1.1 ± 1.3 mm to 2.6 ± 2.1 mm,
respectively (P < 0.01) in the responder group with MAD. The velopharyngeal collapsibility also decreased significantly
from 83.3 ± 21.8% to 46.5 ± 27.1%. The glossopharyngeal collapsibility decreased from 39.8 ± 39.1% to −22.9 ± 73.2% (P
< 0.05).
Conclusion: MAD can be an effective alternative treatment for patients with moderate and severe OSAHS after
surgery. The principal mechanisms underlying the effect of MAD are expansion of the lateral diameter of the
velopharynx, the enlargement of the velopharyngeal area, the reduction of velopharyngeal and glossopharyngeal
collapsibility, and the stabilization of the upper airway.
Keywords: Persistent sleep apnea, Uvulopalatopharyngoplasty, Mandibular advancement devices, Upper Airway,
Computed tomography
Background
Obstructive sleep apnea hypopnea syndrome (OSAHS) is
a common condition that is associated with serious ad-
verse health consequences. Its prevalence is about 2 to 4%
in adults [1]. Continuous positive airway pressure (CPAP)
is the preferred method for treating OSAHS; however,
40% patients with OSAHS cannot tolerate or are unwilling
to accept CPAP treatment [2]. They instead choose to
undergo other treatments, such as surgery. Uvulopalato-
pharyngoplasty (UPPP) is the mainstay surgical approach
in the treatment of patients with palatopharyngeal
obstruction. However, the response rate to this procedure
was only 50% in a short-term follow-up [3]. UPPP plus
genioglossus advancement and hyoid myotomy (GAHM)
has been applied in patients with OSAHS with palatophar-
yngeal and tongue base obstructions, but the response rate
was about 67% [4]. The management of non-responders is
difficult. Usually, CPAP and more invasive operations such
as mandibular and maxillary advancement (MMA) are
recommended, but are rarely accepted. Mandibular
advancement devices (MAD) are non-invasive, cheap,
and usually used in patients with primary snoring or
mild OSAHS. The response rate is 77% [5]. Millman
studied 24 patients who failed UPPP with an adjustable
MAD [6]. Eighteen patients underwent polysomnography
evaluations. Twelve patients had been responders with
MAD in place. MAD treatment might be considered
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for use in non-responders after surgery, but its feasibility
and efficacy must be further demonstrated. The mechan-
ism of MAD treatment of sleep apnea is unclear. In this
study, 19 non-responders after upper airway surgery were
given non-adjustable MAD. The feasibility, the efficacy,
and the mechanism of MAD in the treatment of persistent
sleep apnea after surgery were evaluated.
Methods
Subjects
The inclusive criteria are: 1. Subjects accepted PSG examin-
ation at least 6 months after operation, and post-operation
moderate or severe OSAHS were diagnosed. 2. Patients
wanted to accept therapy but refused to accept CPAP or
reoperation. 3. Patients without occlusal lower respiratory
disorders, periodontal disease or the temporomandibular
joint (TMJ) diseases. The exclusive criteria are: 1. Patients
with central sleep apnea. 2. Patients with severe respiratory
disorders. 3. Patients with nasal obstructive diseases. 4. The
maximal jaw forward distance is less than 6 mm. 5. Patients
with the alveolar bone resorption. 6. The crown root ratio
is over 2:1. 111 post-operation OSAHS patients were
followed up, only 19 patients (17 men, 2 women) with four
surgical procedures met the inclusive criteria, which were
Han-uvulopalatopharyngoplasty (HUPPP) (9), HUPPP +
GAHM (1), Z-palatopharyngoplasty (ZPPP) [5] (2), and
ZPPP +GAHM (7). Subjects with persistent OSAHS had
an average age of 42.4 years (23–58 years), average body
mass index (BMI) of 28.2 kg/m2 (21.2–33 kg/m2), and aver-
age apnea hypopnea index (AHI) of 44.2/h (20.5–83.7/h).
All patients were given non-adjustable MAD called
Snore Guards after polysomnographic recordings and
investigation of Epworth sleepiness scale (ESS) with an
average of 28.6 months after the surgical procedures. Six
months after the application of MAD, all patients again
underwent all investigations described above. The
efficacy and the side effects of MAD were also judged
subjectively by a questionnaire before the last sleep
study, including the sleep quality of the previous night,
patient satisfaction with the device, and side effects.
To determine the mechanism of MAD and the
morphological changes in the upper airway that result
from its application, computed tomography (CT) of the
upper airway was conducted during a daytime nap
induced by intravenous midazolam [7, 8] with and
without MAD in place.
Polysomnography
The sleep studies were carried out in the Sleep Disorders
Center of the Affiliated Sixth People’s Hospital of Shanghai
Jiao Tong University. Apnea was defined as the total
cessation of airflow that was >10 s. Hypopnea was defined
as an event that met two of the following three criteria: (1)
a decrease in airflow of >50%; (2) an EEG arousal as
defined by the American Sleep Disorders Association
scoring criteria; or (3) oxygen desaturation of >3%.
OSAHS was defined as an AHI of more than five episodes
per hour during sleep in patients with symptoms of the
disorder [9]. Therapeutically effective is defined as a
decrease in AHI of >50% of that before treatment with
MAD in place. Treatment success was defined as AHI <5/h
with MAD in place [10].
Upper airway CT
Upper airway CT (Lightspeed VCT, GE, Finland) was
performed in seventeen patients (two patients didn’t
accept CT examination because of personal reasons)
before and after MAD application under three conditions:
quiet breathing, the end of deep inspiration, and apnea.
The time of CT acquisition is about one breathing cycle.
All CT images were reconstructed from the middle sagit-
tal planes. The planes of the upper airway at the level of
the nasopharynx (the extension cord over the lower edge
of the hard palate), the velopharynx (the tip of the uvula),
the glossopharynx (the narrowest part of the glossophar-
ynx), and the epiglotopharynx (5-mm below the tip of the
epiglottis) were obtained during the phase of quiet tidal
breathing, end of deep inspiration, and sleep apnea/
hypopnea. The cross-sectional area, anterior-posterior
diameter, and lateral diameter of each plane of the upper
airway were manually measured by using electronic
calipers by the same technician. The degree of collapse
was calculated as follows: (quiet breathing cross-sectional
area at the end of deep breathing or sleep apnea) / cross-
sectional area during quiet breathing [9]. CT scans were
evaluated by the same investigator who was blinded to
both responders and non-responders. We informed all
patients about the purposes of the CT examination, as
well as the short-term potential hazards or long-term
complications caused by frequent radiation examinations,
after which all patients signed an informed consent. With
55 months of follow-up, no side effects or adverse
reactions were seen to be from radiation exposure.
MAD
Before the intervention of MAD, a clinical examination of
the stomatognathic system, which included measurement
of mandibular mobility, palpation of the temporomandibu-
lar joints and masticatory muscles, and recording of pain
when the mandibular moved forward, was performed. In
the present study, the same dentist took care of all patients,
and the same dental technician was responsible for the
preparation of all appliances.
We used a MAD called ‘Snore Guard’ (Xintai Ltd.,
Beijing) for the advancement of the mandible (Figs. 1
and 2). The degree of mandibular advancement induced
by MAD was adjusted according to the anatomy and
tolerance of the individual patient. Patients tried only
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one position during therapy. In former studies [11–18],
physicians measured the maximum distance of man-
dibular advancement, then choose the position which is
about 75% of the maximum distance and did the MAD
moulding at the position following the product instruc-
tion. The goal was to minimize nocturnal apnea and
snoring while maintaining a comfortable fit. In our
study, the mandibular protrusive maneuver of each
subject was measured. The averaged distances were 5 to
7 mm, which varied from 51 to 100% of patients’
maximum protrusive maneuver. After the last fitting,
patients were asked to wear the device every night
during sleep. The patients were encouraged to wear the
device regularly by telephone as well as when they
returned for visits at our office [11–14].
Statistical analysis
Statistical analysis was performed using SPSS version 18.0.
The paired-samples t-test was used to compare variables of
PSG results and CT parameters pre- and post-treatment
with MAD. One-way analysis of variance (ANOVA) was
used for comparisons of PSG results and CT parameters
between the responder and non-responder groups. All
parametric results were expressed as means ± standard
deviation (SD). A statistically significant difference was
defined as P < 0.05 for all parameters.
Results
Polysomnographic results
All-night polysomnographic data of 19 patients were
available. Patients were grouped into responders and
non-responders according to criteria described in the
Method portion. The AHI in both groups was 44.2 ±
19.2/h, and the LSaO2 was 77.2% ± 7.6% post-surgically;
i.e., before the application of MAD. The AHI decreased
significantly to 28.2 ± 24.6/h and the LSaO2 increased
to 79.3 ± 10.4% with MAD (Table 1). While in the
Fig. 1 Snore Guard XT-1B (produced by Xintai Company, Peking)
Fig. 2 Lateral view before wearing an MAD (a), Lateral view after wearing an MAD (b), Front view before wearing an MAD (c), Front view after
wearing an MAD (d)
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responder group, the AHI decreased significantly from
41.2 ± 13.1/h to 10.1 ± 5.6/h, and the LSaO2 increased
significantly from 78.1 ± 8.9% to 85.4 ± 6.5% with
MAD (Tables 2 and 3).
Eleven patients were classified as responders,two of
whom were complete response with MAD as shown by
an AHI of less than five, and eight as non-responders;
the response rate was 57.9% (11/19). The ESS decreased
from 8.6 to 6.1 after the application of MAD. None of
the patients had a substantial change in body measure-
ments during the study (Tables 2 and 3).
Upper airway CT results
In this study, cephalometric examinations were taken both
without and with MAD in place, but the result showed no
significant difference. As a three-dimensional imaging
examination, CT showed more accurate changes in the
upper airway (Fig. 3). Upper airway CT was performed in
17 patients before and after the MAD application
(Table 4). In non-responders, the change was not signifi-
cance before and after the MAD application, which is not
explained in text.
During the phase of quiet tidal breathing, the velophar-
yngeal cross-sectional area and the lateral diameters of the
velopharynx and nasopharynx were much larger with
MAD in place than without MAD in the responder group
(46.4 ± 26.4 mm2 vs. 26.8 ± 19.0 mm2, 12.4 ± 4.7 mm vs.
9.7 ± 6.3 mm, and 16.5 ± 5.1 mm vs.11.8 ± 6.6 mm,
respectively; P < 0.05).
During the state of deep inspiration, the changes in
the upper airway did not reach statistical significance in
both the responder and non-responder groups.
During sleep apnea/hypopnea, the cross-sectional area,
anterior-posterior diameter, and lateral diameter of the
velopharynx were significantly enlarged at 5.0 ± 6.4 mm2 to
21.2 ± 10.5 mm2, 1.3 ± 1.2 mm to 2.9 ± 0.9 mm, and 2.2 ±
2.3 mm to 8.2 ± 3.8 mm, respectively (P < 0.01) in the re-
sponder group with MAD in place (Table 4). The velophar-
yngeal collapsibility of the responder group decreased
significantly from 83.3 ± 21.8% to 46.5 ± 27.1% with MAD
in place (P < 0.01), and glossopharyngeal collapsibility
decreased from 39.8 ± 39.1% to −22.9 ± 73.2% (P < 0.05)
(Table 5).
Side effects
After wearing MAD all night for 1 week, various side
effects of different degrees occurred in all patients, includ-
ing weak occlusion (1/19), excessive saliva (6/19), dry
mouth (2/19), temporomandibular joint aches (1/19),
dental soreness (9/19), toothache (1/19), loose lower
incisors (2/19), mucosal ulceration (2/19), and masseter
muscle pain (3/19). However, all patients were able to
continue the treatment, and all symptoms were relieved in
1 month with timely and appropriate care.
Compliance
With reference to the definition of CPAP compliance [15],
we considered wearing the MAD for >70% of nights and
wearing it for >4 h per night as good MAD treatment
compliance. In this study, 63.2% (12/19) of patients had
good compliance; in fact, these patients wore the MAD all
night. Among the patients with poor compliance, three
wore the MAD <3 days per week because of loose lower
incisors in two patients after UPPP (HUPPP or ZPPP)
combined with GAHM, and gum pain caused by MAD
deformation in one patient. One patient wore the MAD
Table 1 Body measurement data and ESS and PSG parameters
before and after MAD treatment
Parameters Before MAD After MAD P value
BMI (kg/m2) 28.2 ± 3.2 26.9 ± 7.0 0.373
ESS 8.6 ± 6.2 6.1 ± 6.1 0.025
(S3 + S4)% 12.9 ± 6.5 14.3 ± 8.7 0.459
AHI (/h) 44.2 ± 19.2 28.2 ± 24.6 0.005
LSaO2 (%) 77.2 ± 7.6 79.3 ± 10.4 0.327
Abbreviations: BMI average body mass index, ESS epworth sleepiness scale, (S3
+ S4)% the percentage of stage 3 and stage 4 sleep (deep sleep) in the total
sleep time, AHI apnea hypopnea index, LSaO2 lowest oxygen saturation
Table 2 Body measurements, ESS results between responders
and non-responders before treatment
Parameters Responders Non-responders P value
BMI(kg/m2) 27.9 ± 3.3 28.5 ± 3.3 0.709
Neck circumference (cm) 41.6 ± 1.9 40.0 ± 3.2 0.199
Waist circumference (cm) 100.6 ± 7.4 99.7 ± 8.8 0.804
Hip circumference (cm) 104.0 ± 6.9 104.5 ± 6.2 0.860
Waist-to-hip ratio 1.0 ± 0.1 1.0 ± 0.1 0.578
ESS 7.4 ± 6.1 9.9 ± 6.4 0.401
AHI (/h) 41.2 ± 13.1 47.6 ± 24.8 0.487
LSaO2 (%) 78.1 ± 8.9 76.2 ± 6.1 0.604
Abbreviations: BMI average body mass index, ESS Epworth sleepiness scale, AHI
apnea hypopnea index, LSaO2 lowest oxygen saturation
Table 3 Body measurements, ESS results between responders
and non-responders after treatment
Parameters Responders Non-responders P value
BMI(kg/m2) 27.6 ± 2.4 26.2 ± 10.1 0.674
Neck circumference (cm) 40.9 ± 1.6 40.1 ± 3.1 0.482
Waist circumference (cm) 96.7 ± 7.5 100.1 ± 9.3 0.408
Hip circumference (cm) 100.6 ± 4.5 103.1 ± 5.0 0.271
Waist-to-hip ratio 1.0 ± 0.1 1.0 ± 0.1 0.904
ESS 5.4 ± 5.8 6.8 ± 6.6 0.634
AHI (/h) 10.1 ± 5.6 48.4 ± 21.5 0.000
LSaO2 (%) 85.4 ± 6.5 72.6 ± 10.0 0.004
Abbreviations: BMI average body mass index, ESS Epworth sleepiness scale, AHI
apnea hypopnea index,LSaO2 Lowest oxygen saturation
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Fig. 3 CT scan of responders under the condition of sleep apnea. Without OA in place: nasopharynx (a), velopharynx (b), glossopharynx (c),
epiglotopharynx (d). With OA in place: nasopharynx (e), velopharynx (f), glossopharynx (g), epiglotopharynx (h)
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for <4 h per night because of dry mouth. The survey
results had no difference between pre- and post-MAD
treatment for both responders and non-responders. The
pre- and post-MAD treatment ESS scores of responders
were 7.4 ± 6.1 and 5.4 ± 5.8 (P = 0.215), and the quality of
life scores were 5.5 ± 1.5 and 5.6 ± 1.7 (P = 0.772). There
was no difference before and after treatment, which
maybe related with the low compliance of MAD at home.
Discussion
MADs are the most commonly used oral appliances and
recommended in the treatment of snoring and mild to
moderate OSAHS patients, but they were rarely used in
patients with severe OSAHS, especially in those with
persistent OSAHS condition after surgical treatment.
There are multiple MAD designs. Physicians used those
devices intending to protrude the mandible, increase
Table 4 Upper airway CT results of responders (n = 9) (mm2)
Respiratory status Parameters Plane Before MAD After MAD P value
Quiet breathing CSA NP 131.0 ± 115.4 185.3 ± 100.5 0.052
VP 26.8 ± 19.0 46.4 ± 26.4 0.023
GP 103.8 ± 66.9 93.9 ± 50.8 0.533
EP 52.0 ± 26.5 38.5 ± 22.1 0.068
A-P diameter NP 7.7 ± 4.6 9.3 ± 3.5 0.125
VP 2.8 ± 1.6 3.6 ± 1.6 0.181
GP 14.6 ± 5.5 13.9 ± 4.5 0.966
EP 6.6 ± 2.7 5.5 ± 1.7 0.202
Lateral diameter NP 11.8 ± 6.6 16.5 ± 5.1 0.045
VP 9.7 ± 6.3 12.4 ± 4.7 0.008
GP 14.6 ± 5.5 13.9 ± 4.5 0.497
EP 15.1 ± 15.2 8.5 ± 4.2 0.236
Deep inspiration CSA NP 197.3 ± 173.9 205.7 ± 183.1 0.375
VP 18.3 ± 16.3 43.0 ± 37.8 0.186
GP 131.0 ± 3.6 356.0 ± 189.1 0.172
EP 39.3 ± 27.4 83.0 ± 37.4 0.195
A-P diameter NP 9.3 ± 8.1 9.8 ± 8.7 0.423
VP 1.7 ± 2.0 2.4 ± 2.2 0.277
GP 8.1 ± 1.4 13.8 ± 7.9 0.264
EP 5.4 ± 1.0 8.9 ± 1.7 0.145
Lateral diameter NP 14.6 ± 12.9 15.1 ± 13.6 0.580
VP 6.7 ± 7.7 11.6 ± 10.7 0.199
GP 19.0 ± 2.5 28.5 ± 7.4 0.197
EP 9.1 ± 7.3 10.6 ± 5.9 0.537
Sleep apnea /hypopnea CSA NP 133.8 ± 109.3 163.9 ± 94.5 0.082
VP 5.0 ± 6.4 21.2 ± 10.5 0.000
GP 77.0 ± 68.6 86.0 ± 51.3 0.684
EP 87.4 ± 84.5 66.4 ± 50.4 0.533
A-A-P diameter NP 7.1 ± 4.6 8.7 ± 3.7 0.171
VP 1.3 ± 1.2 2.9 ± 0.9 0.001
GP 8.9 ± 6.8 9.3 ± 4.5 0.813
EP 10.2 ± 6.7 8.5 ± 4.1 0.442
Lateral diameter NP 12.0 ± 6.7 15.7 ± 6.1 0.080
VP 2.2 ± 2.3 8.2 ± 3.8 0.001
GP 9.6 ± 7.8 11.5 ± 4.4 0.427
EP 9.4 ± 6.9 9.3 ± 5.2 0.985
Abbreviations: CSA cross-sectional area, A-P anterior-posterior diameter, NP nasopharynx, VP velopharynx,GP glossopharynx, EP epiglopharynx
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tension of soft tissues as the soft palate, lateral
pharyngeal walls and the tongue, and improve the airway
patency [16]. Many studies were done in past decades,
but the mechanism underlying the efficacy of MAD for
the treatment of OSAHS was still controversial in terms
of whether it helped enlarge the volume of the pharynx
cavity or increased the airway stability. Zhao et al. used
MAD to treat 11 patients with moderate to severe
OSAHS without surgery [12]. In their study, magnetic
resonance imaging (MRI) scans were performed at each
time when the lower jaw were moved forward by 0, 2, 4,
6, or 8 mm while patients were wakeful or during sleep
apnea/hypopnea. They found that during sleep apnea/
hypopnea, the velopharyngeal cross-sectional area with
MAD in place was larger than that without MAD,
especially the coronal axis. No statistically significant
changes in sagittal diameter were found between the
various mandibular advancements. In our study, the velo-
pharyngeal cross-sectional area, the coronal axis, and the
sagittal diameter with MAD in place were all larger than
those without MAD, and the difference was statistically
significant. Upper airway CT imaging showed that the
velopharyngeal cross-sectional area and lateral diameter of
the velopharynx were significantly enlarged in the MAD
responders, but not non-responders, during quiet tidal
breathing and sleep apnea/hypopnea. The result was
consistent with previous reports [13, 17, 18].
According to Schwartz et al’s study [19], a negative pres-
sure of about −13 cm H2O under normal circumstances
could cause airway collapse. Huang et al. [20] also
measured airway pressures in patients with OSAHS after
various treatments. The pressure was −21 cm H2O with
MAD in place, −18 cm H2O after UPPP, and −17 cm H2O
after the soft palate implant surgery. These results showed
that the airway would not collapse as easily if the patients
were wearing a MAD. In our study, The velopharyngeal
and the glossopharyngeal collapsibility of the responder
group was significantly decreased from 83.3 ± 21.8% to
46.5 ± 27.1% and from 39.8 ± 39.1% to −22.9 ± 73.2%,
respectively (P < 0.05). These results are consistent with
those of previous studies too [13, 17, 20–22].
The results of our study showed that MAD could expand
the velopharyngeal coronal axis, enlarge the velopharyngeal
cross-sectional area by mandibular advancement, and
reduce velopharyngeal and glossopharyngeal collapsibility,
resulting in stabilization of the upper airway. During the
phase of quiet tidal breathing, the cross-sectional area of
nasopharyngeal in the responder group without MAD in
place were less than the non-responder group. In further
study, we would do some research to validate whether it
could be used as a predictor of respond on MAD.
Thus, MAD treatment might be considered for
patients with persistent VP or GP, especially VP obstruc-
tion after surgery if they are unable to tolerate CPAP
and refuse more invasive surgery. Thus, MAD might be
an effective and feasible treatment for non-responding
patients after upper airway surgery.
The small number of patients and lack of a control
group or randomization probably decrease the power of
the study. The multiple different pharyngeal and hypo-
pharygneal procedures that were performed decrease the
internal and external validity of the study. In our study, we
followed 111 post-operational patients in total, and only
19 patients matched the inclusion criteria. Because of the
limited number of patients and four types different surgi-
cal procedures, we were not able to separate all subjects
into groups. Therefore, the correlation between specific
surgeries and changes on CT imaging could haven’t been
investigated. We have compared the physical examination
results and AHIs of both responders and non-responders,
and the results showed no significant different. We will
conduct a blinded, controlled, larger prospective study, try
to include more subjects and use adjustable MAD in the
treatment. Hopefully better efficacy could be seen.
Conclusions
Post-operational MAD treatment can be an effective al-
ternative for patients with moderate and severe OSAHS
after surgery. The principal mechanisms underlying the
effect of MAD treatment are the expansion of the lateral
diameter of the velopharynx, the enlargement of the
velopharyngeal area, the reduction of the velopharyngeal
and glossopharyngeal collapsibility, and the stabilization
of the upper airway.
Abbreviations
AHI: The apnea hypopnea index; ANOVA: One-way analysis of variance;
A-P: Anterior-posterior diameter; BMI: Average body mass index;
CPAP: Continuous positive airway pressure; CSA: Cross-sectional area;
CT: Computed tomography; EP: Epiglopharynx; ESS: Epworth sleepiness scale;
GAHM: Genioglossus advancement and hyoid myotomy; GP: Glossopharynx;
MAD: Mandibular advancement devices; MMA: Mandibular and maxillary
advancement; NP: Nasopharynx; OSAHS: Obstructive sleep apnea hypopnea
syndrome; PSG: Polysomnography; SD: Standard deviation; TMJ: The
temporomandibular joint; UPPP: Uvulopalatopharyngoplasty;
VP: Velopharynx; ZPPP: Z-palatopharyngoplasty
Table 5 Collapsibility of the responder group before and after
MAD treatment (%)
Respiratory status Plane Before MAD After MAD P value
Deep inspiration NP 50.9 ± 69.4 47.5 ± 74.3 0.500
VP 65.7 ± 48.5 6.5 ± 132.3 0.500
GP 10.2 ± 28.1 −187.2 ± 26.4 0.123
EP 20.6 ± 44.5 −72.3 ± 8.5 0.244
Sleep apnea /hypopnea NP 7.4 ± 91.2 −20.0 ± 101.3 0.591
VP 83.3 ± 21.8 46.5 ± 27.1 0.005
GP 39.8 ± 39.1 −22.9 ± 73.2 0.031
EP −41.6 ± 101.6 −150.1 ± 176.9 0.066
Abbreviations: A-P anterior-posterior diameter, NP nasopharynx, VP velopharynx,
GP glossopharynx, EP epiglopharynx
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